Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study

G. VETRUGNO^{1,2}, P. LAURENTI^{3,4}, F. FRANCESCHI⁵, F. FOTI¹, F. D'AMBROSIO⁴, M. CICCONI¹, D.I. LA MILIA³, M. DI PUMPO⁴, E. CARINI⁴, D. PASCUCCI^{3,4}, S. BOCCIA^{3,4}, R. PASTORINO³, G. DAMIANI^{3,4}, F. DE-GIORGIO², A. OLIVA², N. NICOLOTTI⁶, A. CAMBIERI⁶, R. GHISELLINI¹, R. MURRI⁷, G. SABATELLI⁸, M. MUSOLINO⁹, A. GASBARRINI¹⁰; GEMELLI-AGAINST-COVID GROUP*

¹Risk Management Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy ²Section of Legal Medicine, Department of Health Surveillance and Bioethics, Università Cattolica del Sacro Cuore, Rome, Italy

³Department of Woman and Child Health and Public Health – Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

⁴Section of Hygiene, University Department of Health Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy

⁵Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy

⁶Medical Management, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy ⁷Institute of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universitá Cattolica del Sacro Cuore, Rome, Italy

⁸Latium Regional Clinical Risk Management Unit, Rome, Italy

⁹Rieti Healthcare Department, Rieti, Italy

¹⁰Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Institute of Special Medical Pathology and Medical Semeiotics, Università Cattolica del Sacro Cuore, Rome, Italy

G. Vetrugno and P. Laurenti contributed equally to this work

Abstract. – OBJECTIVE: To develop a deep learning-based decision tree for the primary care setting, to stratify adult patients with confirmed and unconfirmed coronavirus disease 2019 (COVID-19), and to predict the need for hospitalization or home monitoring.

PATIENTS AND METHODS: We performed a retrospective cohort study on data from patients admitted to a COVID hospital in Rome, Italy, between 5 March 2020 and 5 June 2020. A confirmed case was defined as a patient with a positive nasopharyngeal RT-PCR test result, while an unconfirmed case had negative results on repeated swabs. Patients' medical history and clinical, laboratory and radiological findings were collected, and the dataset was used to train a predictive model for COVID-19 severity. **RESULTS:** Data of 198 patients were included in the study. Twenty-eight (14.14%) had mild disease, 62 (31.31%) had moderate disease, 64 (32.32%) had severe disease, and 44 (22.22%) had critical disease. The G^2 value assessed the contribution of each collected value to decision tree building. On this basis, SpO2 (%) with a cut point at 92 was chosen for the optimal first split. Therefore, the decision tree was built using values maximizing G^2 and LogWorth. After the tree was built, the correspondence between inputs and outcomes was validated.

CONCLUSIONS: We developed a machine learning-based tool that is easy to understand and apply. It provides good discrimination in stratifying confirmed and unconfirmed COVID-19 patients with different prognoses in every con-

Corresponding Author: Federica Foti, MD; e-mail: fotifederica89@gmail.com

text. Our tool might allow general practitioners visiting patients at home to decide whether the patient needs to be hospitalized.

Key Words:

COVID-19, SARS-CoV-2, General practitioners, Primary health care, Machine learning, Community-based care.

*Gemelli-Against-Covid Group, Rome, Italy V. Abbate, N. Acampora, G. Addolorato, F. Agostini, M.E. Ainora, K. Akacha, E. Amato, F. Andreani, G. Andriollo, M.G. Annetta, B.E. Annicchiarico, M. Antonelli, G. Antonucci, G.M. Anzellotti, A. Armuzzi, F. Baldi, I. Barattucci, C. Barillaro, F. Barone, R.D.A. Bellantone, A. Bellieni, G. Bello, A. Benicchi, F. Benvenuto, L. Berardini, F. Berloco, R. Bernabei, A. Bianchi, D.G. Biasucci, L.M. Biasucci, S. Bibbò, A. Bini, A. Bisanti, F. Biscetti, M.G. Bocci, N. Bonadia, F. Bongiovanni, A. Borghetti, G. Bosco, S. Bosello, V. Bove, G. Bramato, V. Brandi, T. Bruni, C. Bruno, D. Bruno, M.C. Bungaro, A. Buonomo, L. Burzo, A. Calabrese, M.R. Calvello, C. Cambise, G. Cammà, M. Candelli, G. Canistro, A. Cantanale, G. Capalbo, L. Capaldi, E. Capone, E. Capristo, L. Carbone, S. Cardone, S. Carelli, A. Carfi, A. Carnicelli, C. Caruso, F.A. Casciaro, L. Catalano, P. Cattani, R. Cauda, A.L. Cecchini, L. Cerrito, M. Cesarano, A. Chiarito, R. Cianci, S. Cicchinelli, A. Ciccullo, M. Cicetti, F. Ciciarello, A. Cingolani, M.C. Cipriani, M.L. Consalvo, G. Coppola, G.M. Corbo, A. Corsello, F. Costante, M. Costanzi, M. Covino, D. Crupi, S.L. Cutuli, S. D'Addio, A. D'Alessandro, M.E. D'Alfonso, E. D'Angelo, F. D'Aversa, F. Damiano, G.M. De Berardinis, T. De Cunzo, D.K. De Gaetano, G. De Luca, G. De Matteis, G. De Pascale, P. De Santis, M. De Siena, F. De Vito, V. Del Gatto, P. Del Giacomo, F. Del Zompo, A.M. Dell'Anna, D. Della Polla, L. Di Gialleonardo, S. Di Giambenedetto, R. Di Luca, L. Di Maurizio, M. Di Muro, A. Dusina, D. Eleuteri, A. Esperide, D. Fachechi, D. Faliero, C. Falsiroli, M. Fantoni, A. Fedele, D. Feliciani, C. Ferrante, G. Ferrone, R. Festa, M.C. Fiore, A. Flex, E. Forte, A. Francesconi, L. Franza, B. Funaro, M. Fuorlo, D. Fusco, M. Gabrielli, E. Gaetani, C. Galletta, A. Gallo, G. Gambassi, M. Garcovich, I. Gasparrini, S. Gelli, A. Giampietro, L. Gigante, G. Giuliano, G. Giuliano, B. Giupponi, E. Gremese, D.L. Grieco, M. Guerrera, V. Guglielmi, C. Guidone, A. Gullì, A. Iaconelli, A. Iafrati, G. Ianiro, A. Iaquinta, M. Impagnatiello, R. Inchingolo, E. Intini, R. Iorio, I.M. Izzi, T. Jovanovic, C. Kadhim, R. La Macchia, F. Landi, G. Landi, R. Landi, R. Landolfi, M. Leo, P.M. Leone, L. Levantesi, A. Liguori, R. Liperoti, M.M. Lizzio, M.R. Lo Monaco, P. Locantore, F. Lombardi, G. Lombardi, L. Lopetuso, V. Loria, A.R. Losito, B.P.L. Mothanje, F. Macagno, N. Macerola, G. Maggi, G. Maiuro, F. Mancarella, F. Mangiola, A. Manno, D. Marchesini, G.M. Maresca, G. Marrone, I. Martis, A.M. Martone, E. Marzetti, C. Mattana, M.V. Matteo, R. Maviglia, A. Mazzarella, C. Memoli, L. Miele, A. Migneco, I. Mignini, A. Milani, D. Milardi, M. Montalto, G. Montemurro, F. Monti, L. Montini, T.C. Morena, V. Mora, C. Morretta,

D. Moschese, C.A. Murace, M. Murdolo, M. Napoli, E. Nardella, G. Natalello, D. Natalini, S.M. Navarra, A. Nesci, A. Nicoletti, R. Nicoletti, T.F. Nicoletti, R. Nicolò, E.C. Nista, E. Nuzzo, M. Oggiano, V. Ojetti, F. Cosimo Pagano, G. Paiano, C. Pais, F. Pallavicini, A. Palombo, F. Paolillo, A. Papa, D. Papanice, L.G. Papparella, M. Paratore, G. Parrinello, G. Pasciuto, P. Pasculli, G. Pecorini, S. Perniola, E. Pero, L. Petricca, M. Petrucci, C. Picarelli, A. Piccioni, A. Piccolo, E. Piervincenzi, G. Pignataro, R. Pignataro, G. Pintaudi, L. Pisapia, M. Pizzoferrato, F. Pizzolante, R. Pola, C. Policola, M. Pompili, F. Pontecorvi, V. Pontecorvi, F.R. Ponziani, V. Popolla, E. Porceddu, A. Porfidia, L.M. Porro, A. Potenza, F. Pozzana, G. Privitera, D. Pugliese, G. Pulcini, S. Racco, F. Raffaelli, V. Ramunno, G.L. Rapaccini, L. Richeldi, E. Rinninella, S. Rocchi, B. Romanò, S. Romano, F. Rosa, L. Rossi, R. Rossi, E. Rossini, E. Rota, F. Rovedi, C. Rubino, G. Rumi, A. Russo, L. Sabia, A. Salerno, M. Sali, S. Salini, L. Salvatore, D. Samori, C. Sandroni, M. Sanguinetti, R. Santangelo, L. Santarelli, P. Santini, D. Santolamazza, A. Santoliquido, F. Santopaolo, M.C. Santoro, F. Sardeo, C. Sarnari, A. Saviano, L. Saviano, F. Scaldaferri, R. Scarascia, T. Schepis, F. Schiavello, G. Scoppettuolo, D. Sedda, F. Sessa, L. Sestito, C. Settanni, M. Siciliano, V. Siciliano, R. Sicuranza, B. Simeoni, J. Simonetti, A. Smargiassi, P.M. Soave, C. Sonnino, D. Staiti, C. Stella, L. Stella, E. Stival, E. Taddei, R. Talerico, E. Tamburello, E. Tamburrini, E.S. Tanzarella, E. Tarascio, C. Tarli, A. Tersali, P. Tilli, J. Timpano, E. Torelli, F. Torrini, M. Tosato, A. Tosoni, L. Tricoli, M. Tritto, M. Tumbarello, A.M. Tummolo, M.S. Vallecoccia, F. Valletta, F. Varone, F. Vassalli, G. Ventura, L. Verardi, L. Vetrone, E. Visconti, F. Visconti, A. Viviani, R. Zaccaria, C. Zaccone, C. Zanza, L. Zelano, L. Zileri Dal Verme, G. Zuccalà.

Introduction

Machine learning techniques find patterns to allow prediction from raw data and are increasingly used in medicine because of their high accuracy. Decisional trees provide a science-based tool that is particularly appropriate to apply the principles of personalized medicine, as previously highlighted¹, and can be immediately applied for clinical decision-making.

Machine learning was previously applied during the coronavirus disease 19 (COVID-19) emergency to detect vaccines/medicines and to predict respiratory failure in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) patients¹⁻³. However, to our knowledge, no study has investigated the need for hospitalization of COVID-19 patients.

Since the beginning of the pandemic, several publications have shown clinical and laboratory features associated with COVID-19 severity^{4,5}, which are categorized as mild, moderate, severe and critical.

Starting from these definitions, we assumed that mild and moderate types could be monitored and treated at home, while severe and critical types require mechanical ventilation, close follow-up and, therefore, hospitalization.

The aim of our study was to stratify COVID-19 patients through a machine-learning technique to accurately and efficiently decide between home monitoring and hospitalization in a primary care setting before Reverse Transcription-Polymerase Chain Reaction (RT-PCR) test results of nasal and pharyngeal swab specimens are available.

Patients and Methods

For our retrospective cohort study, we analysed data of confirmed and unconfirmed COVID-19 patients⁶ admitted to COVID-19 wards of the Fondazione Policlinico A. Gemelli IRCCS, which is a tertiary care university hospital in Rome, Italy, between 5 March 2020 and 5 June 2020. At this aim, we extracted demographic data, clinical symptoms, comorbidities, laboratory and radiological findings (i.e., chest X-rays of the first 24 hours after admission) from medical records.

All patients admitted to the Emergency Department (ED) complaining of fever or other acute respiratory symptoms, such as dyspnoea during the study period were considered for recruitment. Before admission to a hospital ward, all patients had undergone nasal and oropharyngeal swabs for the detection of one or more SARS-CoV-2-specific nucleic acid targets according to the protocol established by the WHO⁷. Patients with negative samples were retested after 48-72 h. The inclusion criteria were fever and/or respiratory symptoms, regardless of RT-PCR results and chest X-ray pattern, and age ≥ 18 years old. Pregnancy was an exclusion criterion. The Ethics Committee approved this research (Prot. ID 3775).

Fever was defined as axillary temperature equal to or higher than 37.5°C at the time of ED admission or a recent referred episode. The presence of immunodeficiency was defined as primitive or secondary due to treatment for cancer. Chest X-ray showing any alteration attributable to phlogosis, or in which phlogosis could not be explained with the presence of other conditions, was considered positive.

A confirmed COVID-19 case was based on positive RT-PCR results on nasopharyngeal swabs⁸, and an unconfirmed case was based on RT-PCR negative results for 2 days or longer (i.e., when the last swab sample was obtained)⁶.

Every patient was categorized as mild, moderate, severe or critical according to illness severity9. Patients with mild disease were defined as symptomatic patients without evidence of viral pneumonia or hypoxia. Moderate disease patients were defined as patients with clinical signs of mild pneumonia, including SpO₂ <90% on room air. Patients with severe disease were defined as patients with clinical signs of pneumonia (such as dyspnoea) plus one of the following symptoms: respiratory rate >30 breaths/min, severe respiratory distress, $SpO_2 < 90\%$ on room air or partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) \leq 300 mmHg. Critically diseased patients were defined as patients with acute respiratory distress syndrome (ARDS), multiple organ failure, sepsis or septic shock.

Statistical Analysis

In our study, decision tree analysis^{10,11} was performed to predict the relationship between the values of certain variables, called the predictors (or factors), and their response values (the "target"). A splitting algorithm recursively chooses a predictor. If the predictor is numeric, a threshold is chosen, and each patient is either assigned in the subset "value of the variable < threshold" or in the subset "value of the variable \geq threshold". If the predictor is categorical, a threshold, which is a partition of the values of the predictor, is used. The splitting pair – variable and threshold/partition – are chosen to maximize the explained variability for target values, which can be obtained by splitting parent sets into more homogeneous subsets. Each subset obtained corresponds to a particular "rule" (which summarizes all the splitting criteria and leads to that subset). Each rule also gives the calculated probability for each value of the target value.

By means of this analysis, a predictive model for outcome observations (mild, moderate, severe and critical) could be obtained from the observation of the input variables considered.

In the present analysis, factors were either continuous or categorical. The outcome variable represents the target for our model. Since it is a categorical variable, the decision tree can be considered a "classification tree". The tree is obtained by splitting in a recursive process the original data (the "root").

The initial condition is represented in Figure 1, where all the cases considered are represented as dots partitioned according to their outcome value.




Figure 1. All the cases are represented as dots partitioned according to their outcome value. Outcome level "A" (green) represents outcome = mild; level "B" (yellow) has outcome = moderate; level "C" (orange) represents outcome = severe; level D (red) has outcome = critical.

Since no classification split is applied (number of splits = 0), RSquare is 0. The term "rate" stands for the proportion of observations for each target level. The term "Prob" is the predicted probability initially given by the rate value.

The G^2 value (likelihood ratio chi-square) is proportional to the entropy associated with the classification level. Entropy measures randomness, and its value is maximum when no split is applied. If only a level for the target value is present at a certain level in splitting, $G^2 = 0$ (perfect fit, no value in trying to split further, so entropy = 0).

When the first split is required, all the variables are characterized by JMP^{\circledast} software, used in the analysis, to identify the most effective split from the predictive point of view. To obtain the optimal splitting, the splitting variable must be chosen together with the most suitable "cut point". The optimal pair (variable, cut point) is identified as the one that maximizes the LogWorth indicator¹². Usually, the G² value for the optimal variable results is maximized since it represents the decrement in total entropic value G² obtained through splitting.

Results

During the study period, 1583 patients were admitted to the ED, of whom 198 hospitalized patients were finally included to build our decision tree. The majority were male (127; 64.1%), with a mean age of 68.73 (25-103) years. Half of them (n=99, 50%) were positive for SARS-CoV-2 after a nasopharyngeal RT-PCR test, and half were negative even after repeated testing.

At presentation, 175 (88.3%) patients had fever, 113 (57.0%) dyspnoea, 91 (45.9%) dry cough, 32 (16.2%) gastrointestinal symptoms, 28 (14.1%) asthenia, and 17 (8.6%) respiratory symptoms.

Comorbidities were distributed as follows: 100 (50.5%) patients had hypertension, 65 (32.8%) cardio-cerebrovascular disease, 37 (18.6%) chronic obstructive pulmonary disease (COPD), 37 (18.6%) diabetes, 31 (15.6%) malignant neoplasm, 23 (11.6%) chronic kidney disease, 14 (7.0%) immunosuppression and 10 (5.0%) chronic liver disease. Twenty-three (11.6%) patients were current smokers or had a history of smoking. Laboratory characteristics are shown in Table I.

One hundred forty-eight (74.7%) patients had a chest X-ray suggestive of a phlogistic pattern. Regarding SARS-CoV-2 severity, 28 (n=14.14%) patients had mild disease, 62 (31.31%) had moderate disease, 64 (32.32%) had severe disease, and 44 (22.22%) had critical disease (Figure 2).

The contribution to the decision tree building was calculated for each value, as shown in Figure 3. Some of the collected values, such as age and sex, were excluded. The best splitting variable for the first split was SpO2%, with a cut point = 92. The first split is represented in Figure 4 and 5. SpO₂ (%) with a cut point at 92 was chosen for the optimal first split since both G² and LogWorth were maximized. For each candidate, the G² value represents the overall entropy reduction attainable, as shown in the next figure considering the sum of G² values for the split sets ("left" and "right"):

 $G_{candidate}^2 = G_{parent}^2 - (G_{left}^2 + G_{right}^2)$. By iterating this procedure, the trees in Figures 6A-F were obtained. After the tree was built, the correspondence between inputs and outcomes was validated, as shown in Figure 7. Table II shows the confusion matrix with entry values concentrated around the main diagonal because, by definition, B and C outcomes or A and B outcomes are closer to each other than B and D or A and D. However, in the chosen tree algorithms, no proximity criterion is applied and instead it represents

Factor	Min value	Mean value	Max value
Creatine kinase	15	177.0	3615
Creatinine	0.41	1.405	15.72
CRP-C-reactive protein	0.5	97.83	513.7
Ferritin	19	452.4	1775
Hemoglobin	7	13.13	19.5
IL-6 (interleukin)	1.8	54.02	465.3
INR	0.91	1.206	8.06
LDH-Lactate Dehydrogenase	92	367.6	1618
Lymphocytes	0.18	1.477	36.23
Lymphocytes %	1.1	16.22	87.4
Procalcitonin	0.05	1.702	75
Platelets	47	249.3	994
Potassium	3	4.262	7.6
Sodium	123	138.3	156
SpO ₂ (%)	6	91.74	100
Total bilirubin	0.2	0.8724	7.8
Alanine aminotransferase alt (GPT)	5	37.11	609

Table I. Laboratory characteristics of the 198 patients during the first 24 h after admission (some laboratory values are missing).

a result. Moreover, in the data model, the outcome variable (the target) is considered a categorical variable and not a numerical or ordinal variable, for which a proximity criterion could be suggested.

Discussion

We aimed to develop a tool for the primary care setting to allow community-based general practitioners to decide whether a patient needs to be hospitalized. The selected time interval of the study (between 5 March 2020 and 5 June 2020) allowed us to compare the ED of the hospital during the lockdown period with primary care in the current period.

Patients with mild or moderate disease were discharged without receiving mechanical ventilation or were admitted to intensive care units (ICUs). Patients with critical disease usually need intensive support and occasionally have a fatal outcome. Patients with severe disease have a clinical history that was difficult to monitor at home.




Figure 2. Outcome distribution.

We built a decisional tree model in which relationships between clinical-instrumental predictors and outcomes became stronger, and their prediction ability was converted into a decision-making tool. Colours were used with the aim of mimicking risk scales: when the tree was coloured green or yellow, the patients did not require hospitalization.

Column Contributions				
	Number			
Term	of Splits	G^2		Portio
SPO2 (%)		69,7969558		0,207
CHEST X-RAY SUGGESTIVE OF ANY POSSIBLE FLOGISTIC PATTERN		32,6928176		0,097
LDH - LACTATE DEHYDROGENASE		28,7416242		0,085
CREATININE	2	25,668901		0,076
CREATINE KINASE	2	23,3429241		0,069
PLATELETS	1	19,5666098		0,058
INR	1	17,4976508		0,051
PCT - PROCALCITONIN	1	16,2472036		0,048
CRP - C-REACTIVE PROTEIN	1	13,6210481		0,040
ALANINE AMINOTRANSFERASE (ALT/GPT)	2	12,8126434		0.038
HEMOGLOBIN	1	11.315685		0.033
FEVER	1	9.37601348		0.02
DYSPNEA	1	8,90612098		0.026
POTASSIUM		8,70273898		0.029
GASTROINTESTINAL SYMPTOMS		8.10618508		0.024
HEART RATE		7.81811883		0.023
LYMPHOCYTES		7.63817002		0.022
IL-6 (INTERLEUKIN)		7,40737725		0.022
FERRITIN		3.86370974		0,022
SODIUM	1			0,01
GENDER	0	5,70094622	P : : : : :	0.000
	0	0		
AGE	0			0,000
ANOSMIA / AGEUSIA		0		0,000
OTHER RESPIRATORY SYMPTOMS	0	0		0,000
HEADACHE	0	0		0,000
DRY COUGH	0	0		0,000
PRODUCTIVE COUGH	0	0		0,000
MYALGIA / ARTHRALGIA	0	0		0,000
ASTHENIA	0	0		0,00
SMOKING HABIT (CURRENT/HISTORY OF)	0	0		0,000
COPD	0	0		0,000
DIABETES MELLITUS	0	0		0,00
HYPERTENSION	0	0		0,00
CARDIO-CEREBROVASCULAR DISEASE	0	0		0,00
MALIGNANT NEOPLASM (CURRENT/HISTORY OF)	0	0		0,00
CHRONIC LIVER DISEASE	0	0		0,00
CHRONIC KIDNEY DISEASE	0	0		0.000
PRIMARY / SECONDARY IMMUNODEFICIENCY	0	0		0.000
BUN - BLOOD UREA NITROGEN	0	ō		0.00
CONJUGATED BILIRUBIN	0	0		0.000
TOTAL BILIRUBIN	ő	ő		0,00
D-DIMER	ő	ő		0.000
GGT - GAMMA-GLUTAMYL-TRANSFERASE	0	ő		0.000
LEUKOCYTES	0	0		0.00
HS TROPONIN I	0	0		0,00
	0	0		
LYMPHOCITES %	0	0		0,00
ASPARTATE AMINOTRANSFERASE (AST/GOT)				0,000
SARS-COV-2 POSITIVE	0	0		0,000

Figure 3. Contribution of each candidate assessed by G^2 value.

Candidates			
Term	G^2	LogWorth	Cut Point
GENDER	3.35396158	0.468262453	
AGE	14,20783534	1.244780209	
ANOSMIA / AGEUSIA	6.16772991		
FEVER	9 68830079	1.669377818	
SPO2 (%)	43,31128142 *		
HEART RATE	8.95759749		
OTHER RESPIRATORY SYMPTOMS	4,36607898	0,648684351	
HEADACHE	3,32279203		
DRY COUGH	4,13273043	0,402032210	
PRODUCTIVE COUGH	4,34029501		
DYSPNEA		1.101789951	
SASTROINTESTINAL SYMPTOMS	0,93438960	0.087713169	-
MYALGIA / ARTHRALGIA	1,16792129		
	0,19062505	0,009178114	
MOKING HABIT (CURRENT/HISTORY OF)	7,44112007		
COPD	4,86224694	0,378206196	
DIABETES MELLITUS	0,69337132		
IVPERTENSION		1,036686654	
ARDIO-CEREBROVASCULAR DISEASE	8,03772518	1,344492378	
ALIGNANT NEOPLASM (CURRENT/HISTORY OF)	2,79313957		
CHRONIC LIVER DISEASE	5,56660405	0,484230812	
CHRONIC KIDNEY DISEASE	1,38874754		-
RIMARY / SECONDARY IMMUNODEFICIENCY	5,33707541	0,448803705	0
CHEST X-RAY SUGGESTIVE OF ANY POSSIBLE FLOGISTIC PATTERN	38,39391689	7,983129131	0
BUN - BLOOD UREA NITROGEN	15,60705031	1,545450352	
CONJUGATED BILIRUBIN	8,19651663	0,609907922	0,4
OTAL BILIRUBIN	8,76678839	0,444124655	0,3
CREATINE KINASE	28,53993633	4,402589082	280
CREATININE	11,64932661	0,594259988	1,27
D-DIMER	8,45489932	0,309869440	392
IEMOGLOBIN	12,27064517	0,822733143	13,3
ERRITIN	3,59957348	0,015470990	265
GGT - GAMMA-GLUTAMYL-TRANSFERASE	10,40169883	0,799308989	19
EUKOCYTES	9.33240806	0.170652054	3.21
IS TROPONIN I	11.63828230	0.902806790	86
L-6 (INTERLEUKIN)	8.65685602	0.401965828	22.7
NR	10.09353706	0.549289455	
DH - LACTATE DEHYDROGENASE	33,56641748		
YMPHOCYTES	13,98696927	0.952656409	
YMPHOCITES %	17.51839175	1.538907139	
LATELETS	7.92738328	0,108872428	
OTASSIUM	7,83613275	0,301397944	
CT - PROCALCITONIN	20,91212965		
CRP - C-REACTIVE PROTEIN	28,29733538	4.115633361	
ODIUM	13.28160618		
ALANINE AMINOTRANSFERASE (ALT/GPT)	13,37188080	1.034079801	
ASPARTATE AMINOTRANSFERASE (AST/GOT) SARS-COV-2 POSITIVE	11,92543252 4,83459527	0,909304144 0,734433751	

Figure 4. G², LogWorth and cut point are shown for each candidate.

This model is different from others already published because of patient extraction (CO-VID-19 negativity at RT-PCR test was not considered an exclusion criterion, as is usual in previous studies). Moreover, the model is easy to understand and apply, allowing rapid evaluation in every context, considering that general practitioners need to stratify patients before results are available.

During the first wave of the pandemic, general practitioners were overwhelmed due to the lack of adequate personal protective equipment¹³. Currently, they should regain their function as playmakers in the management of suspected cases of COVID-19 in the primary care setting^{14,15} with the aim of reducing unnecessary hospital admissions and containing the risk of ED and ICU overcrowding. In fact, when lockdown measures were adopted at the beginning, the exponential growth of COVID-19 patients was taken over by the hospital network, which required resource redistribution and reorganization of some care chains in COVID-19 units. Questions have been

raised regarding whether the saturation of health services is an inevitable consequence of the pandemic¹⁶. Some authors¹⁷ have emphasized the role of hygienic and behavioral measures, such as mask wearing, physical distancing and hand hygiene, to limit the spread of COVID-19 and support the health system in modulating offerings. Others¹⁸ have stressed the importance of contact tracing as a strategy to eliminate the virus, disseminating diagnostic tests to isolate cases in a timely manner. However, these solutions may not be sufficient if not combined with other solutions that aim to relieve the pressure on hospitals given that the lack or delay of non-COVID patient treatment may have short- and medium-term effects on their survival^{19,20}. For this purpose, new strategies to optimize home-based COVID-19 patient management were designed, including end-of-life support for patients unlikely to benefit from intensive care²¹. In this regard, several models predicting the need for ICU assistance or mortality




Figure 5. Sum of G^2 values for the split sets and view of the optimal first split using SpO₂ with a cut-off point of 92 (A= mild outcome; B= moderate outcome; C= severe outcome; D= critical outcome).




Figure 6. Decision tree split for better view (Panel A: As if $\text{SpO}_2 < 92$; Panel B: As if $\text{SpO}_2 \ge 92$; Panel C: As if $\text{SpO}_2 \ge 92$ and CHEST X-RAY negative; Panel D: As if $\text{SpO}_2 \ge 92$ and CHEST X-RAY positive; Panel E: As if $\text{SpO}_2 \ge 92$, CHEST X-RAY positive and LDH ≥ 291 ; Panel F: As if $\text{SpO}_2 \ge 92$, CHEST X-RAY positive and LDH ≤ 291 ; Panel F: As if $\text{SpO}_2 \ge 92$, CHEST X-RAY positive and LDH ≤ 291 ; Panel F: As if $\text{SpO}_2 \ge 92$, CHEST X-RAY positive and LDH ≤ 291).




Figure 7. Receiver operating characteristic (ROC) curves (outcome type A= mild; B= moderate; C= severe; D= critical).

have been developed²²⁻²⁴. However, as the latest version of a living systematic review published in BMJ recently highlighted, all 232 prediction models for the diagnosis and prognosis of COVID-19 "remain at high or unclear risk of bias" and still need to be validated²⁵.

Our study has some limitations. First, the dataset was based on a relatively small, single hospital-based cohort. In this regard, this can be seen as a preliminary study with the aim of developing a new approach. The dataset considered here can represent a training environment for the predictive model, which could be enlarged in a second step of the work by considering a larger population of patients, as mentioned above, and conducting model testing and validation. Therefore, a confirmatory study is recommended and will be our next step. Second, the variables used were those typically obtainable outside the hospital setting, but analytic methods may not be the same in every setting. Despite these limitations, the present prediction model is strong because the entry values in the confusion matrix (Table II) are concentrated close to the main diagonal, as described in the results. Moreover, the RT-PCR result was not considered in the decision tree, suggesting that testing is not an influencing outcome. These data are even more important if we hypothesize that COVID-19 outbreaks could coincide with seasonal influenza and other viruses causing respiratory diseases, which could be difficult to differentiate because of their similar clinical features (fever, fatigue, dry cough, and expiratory dyspnea). Further studies should address this issue.

Conclusions

To sum up, we developed a machine learning-based tool to predict the need for hospitalization and to assist general practitioners in the primary care setting. Our tool might have potentially important implications for the optimization of quality of care in terms of hospitalization appropriateness, saving resources and decreasing pressure on hospitals, which continue to have a heavy impact on managing the pandemic correctly.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

We would like to thank Davide Cammarata and Antonio Marchetti, Fondazione Policlinico Universitario A. Gemelli IRCCS, for their support in data extraction and Franziska M. Lohmeyer, Ph.D, Fondazione Policlinico Universitario A. Gemelli IRCCS, for her support in revising our manuscript.

Most likely outcome in prediction					
Outcome	А	В	С	D	Total
A	15	10	2	1	28
В	3	46	9	4	62
С		12	46	6	64
D	1		4	39	44
Total	19	68	61	50	198

Table II. Most likely outcome in case of prediction error (outcome type A = mild; B = moderate; C = severe; D = critical).

References

- Ferrari D, Milic J, Tonelli R, Ghinelli F, Meschiari M, Volpi S, Faltoni M, Franceschi G, ladisernia V, Yaacoub D, Ciusa G, Bacca E, Rogati C, Tutone M, Burastero G, Raimondi A, Menozzi M, Franceschini E, Cuomo G, Corradi L, Orlando G, Santoro A, Digaetano M, Puzzolante C, Carli F, Borghi V, Bedini A, Fantini R, Tabbì L, Castaniere I, Busani S, Clini E, Girardis M, Sarti M, Cossarizza A, Mussini C, Mandreoli F, Missier P, Guaraldi G. Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia-Challenges, strengths, and opportunities in a global health emergency. PLoS One 2020; 12; 15: e0239172.
- Alsharif MH, Alsharif YH, Albreem MA, Jahid A, Solyman AAA, Yahya K, Alomari OA, Hossain MS. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2. Eur Rev Med Pharmacol Sci 2020; 24: 11977-11981.
- Perrella A, Carannante N, Berretta M, Rinaldi M, Maturo N, Rinaldi L. Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches? Eur Rev Med Pharmacol Sci 2020; 24: 2162-2164.
- 4) Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720.
- 5) Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Damen JAA, Debray TPA, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Kreuzberger N, Lohman A, Luijken K, Ma J, Andaur CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, van Kuijk SMJ, van Royen FS, Wallisch C, Hooft L, Moons KGM, van Smeden M. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 2020; 369: m1328. Update in: BMJ 2021; 372: n236. Erratum in: BMJ 2020; 369: m2204.
- De Angelis G, Posteraro B, Biscetti F, Ianiro G, Zileri Dal Verme L, Cattani P, Franceschi F, Sanguinetti M, Gasbarrini A. Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features. BMC Infect Dis 2020; 20: 775.
- 7) World Health Organization. (2020). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization. https:// apps.who.int/iris/handle/10665/331329

- WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected 309 human cases. In: Interim guidance. Geneva: World Health Organization; 310 2020. Available at: https://apps. who.int/iris/bitstream/handle/10665/331501/ 311 WHO-COVID-19-laboratory-2020.5-eng.pdf?sequence=1&isAllowed=y.
- 9) World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. https://apps. who.int/iris/handle/10665/332196.
- 10) JMP 14 Predictive and Specialized Modeling (2018), Sas Institute.
- Klimberg R, McCullough BD. Fundamentals of Predictive Analytics with JMP, Second Edition (2016), SAS Press.
- 12) Sall J. (2002), "Monte Carlo Calibration of Distribution od Partition Statistics" SAS Institute. Retrieved July 29, 2015 from https://www.jmp.com/ content/dam/jmp/documents/en/white-papers/ montecarlocal.pdf
- Rimmer A. Covid-19: GPs call for same personal protective equipment as hospital doctors. BMJ 2020; 368: m1055.
- 14) Lopes N, Vernuccio F, Costantino C, Imburgia C, Gregoretti C, Salomone S, Drago F, Lo Bianco G. An Italian Guidance Model for the management of suspected or confirmed COVID-19 patients in the primary care setting. Front Public Health 2020; 8: 572042.
- https://www.simg.it/Coronavirus/Covid_Gestionepaziente-SIMG_1.5.pdf
- 16) Tangcharoensathien V, Bassett MT, Meng Q, Mills A. Are overwhelmed health systems an inevitable consequence of covid-19? Experiences from China, Thailand, and New York State. BMJ 2021; 372: n83.
- 17) Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020; 395: 1973-1987.
- Baker MG, Wilson N, Blakely T. Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases. BMJ 2020; 371: m4907.
- 19) Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020; 371: m4087.
- 20) Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, Aggarwal A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020; 21: 1023-1034. Erratum in: Lancet Oncol 2021; 22: e5.

- Park S, Elliott J, Berlin A, Hamer-Hunt J, Haines A. Strengthening the UK primary care response to covid-19. BMJ 2020; 370: m3691.
- 22) Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM; ISARIC4C investigators. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370: m3339. Erratum in: BMJ 2020; 371: m4334.
- 23) Magro B, Zuccaro V, Novelli L, Zileri L, Celsa C, Raimondi F, Gori M, Cammà G, Battaglia S, Genova VG, Paris L, Tacelli M, Mancarella FA, Enea M, Attanasio M, Senni M, Di Marco F, Lorini LF, Fagiuoli S, Bruno R, Cammà C, Gasbarrini

A. Predicting in-hospital mortality from Coronavirus Disease 2019: a simple validated app for clinical use. PLoS One 2021; 16: e0245281.

- 24) Covino M, De Matteis G, Burzo ML, Russo A, Forte E, Carnicelli A, Piccioni A, Simeoni B, Gasbarrini A, Franceschi F, Sandroni C; GEMELLI AGAINST COVID-19 Group. Predicting in-hospital mortality in COVID-19 older patients with specifically developed scores. J Am Geriatr Soc 2021; 69: 37-43.
- 25) Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Damen JAA, Debray TPA, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Kreuzberger N, Lohman A, Luijken K, Ma J, Andaur CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, van Kuijk SMJ, van Royen FS, Wallisch C, Hooft L, Moons KGM, van Smeden M. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 2020; 369: m1328. Update in: BMJ 2021; 372: n236. Erratum in: BMJ 2020; 369: m2204.